An advisory panel to Japan’s health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug’s official price at about 304.97 million yen. 
   Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country’s most expensive drug.